Upload
phunganh
View
226
Download
0
Embed Size (px)
Citation preview
2013 Annual Report1
“I know where I am, and I know where I’m going and I know I’m going to get there. I’m going to be excited and enthusiastic every day that God gives me on this earth. I am going to dream my dreams.”
– j i m va lva n o
2013 Annual Report1
CEO Message
2
The V Foundation for Cancer Research is a charitable organization
dedicated to saving lives by helping to find cures for cancer. The V
Foundation strives to make a difference by generating extensive,
passionate support for cancer research and by creating an urgent
awareness among all Americans of the importance of ending the
disease in all its forms. The dedicated work of our many partners,
volunteers and supporters has led to many extraordinary, tangible
victories in the war against cancer. Through advocacy, education,
fundraising, and philanthropy, The V Foundation continues to seize
every opportunity to change lives and ultimately defeat cancer.
The V Foundation has spent 21 years funding research that brings
together the brightest minds working to end cancer. We are proud
to present our annual report, providing a snapshot of last year’s
accomplishments. During fiscal year 2013, we funded $14 million in
new cancer research grants, and continue to fund previous multi-
year grants. We are making important progress! This report is also a
prelude to the future – a look at how to expedite this fight, to make
it as effective as possible, to enlist each of you in this effort so that
we can end cancer. Thank you for your help and support. No one
can change the course of cancer alone. We dedicate this report to
everyone working together toward this goal. Please help us continue
until there is no longer a need.
Susan BraunChief Executive Officer
Our Mission
2013 Annual Report
2013 Annual Report3
The V Foundation awards three types of grants. The V Scholar
grant directly funds young investigators to help them establish
their own independent laboratory research projects. The
Translational grant facilitates the transition of projects from the
laboratory to the patient’s beside quickly and efficiently. The
Designated grants are inspired by particular areas of scientific
interest and/or geographic reach. They are selected on the basis
of scientific merit, as determined by our scientific advisors.
v S c h o l a r S
Bjoern Schwer, M.D., Ph.D.Boston Children’s HospitalBoston, MAMartin D. Abeloff, M.D. V ScholarNeural Genome Rearrangements and Alternative end Joining Processes in Initiation and Maintenance of Medulloblstoma
Maximilian Diehn, M.D., Ph.D.Stanford Cancer InstituteStanford, CAInvestigating the KEAP1-NRF2 Pathway in Lung Stem Cells and Lung CancerAlbert Wyrick V Scholar AwardFunded by The Michael and Carole Marks Family
Rafael Bejar, M.D., Ph.D.UCSD Moores Cancer CenterLa Jolla, CA Pathogenic Mechanisms of Splicing Factor Mutations in Myelodysplastic Syndromes
Timothy F. Burns, M.D., Ph.D.University of Pittsburgh Cancer InstitutePittsburgh, PATargeting KRAS Mutant Lung Adenocarcinoma through Inhibition of TWIST 1Supported by UNICO National in Memory of Sue Speciale
Luis Carvajal-Carmona, Ph.D.University of California, DavisSacramento, CA Identification of Novel Breast Cancer Genes in a Hispanic Isolate
Robert Doebele, M.D., Ph.D.University of Colorado School of MedicineDepartment of Medicine, Division of Medical OncologyAurora, CO NTRK1 Gene Fusions as a Novel Oncogene Class and Therapeutic Target in Lung Cancer Funded in Memory of Calvin Bradham with support from Crown Imports
Michael J. Emanuele, Ph.D.Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel Hill, NCIdentification of Ubiquitin Signaling Networks as Novel Avenues for Therapeutic Intervention
Summer Gibbs, Ph.D.Oregon Health & Science UniversityPortland, ORScreening of Small Molecule Fluorophores to Probe Pancreatic Cancer Margins in the Operating Room
2013 Grants
2013 Annual Report 4
Peter Hammerman, M.D., Ph.D.Dana-Farber Cancer InstituteBoston, MATargeting Fibroblast Growth Factor Receptor Fusions in Lung and Head and Neck Cancer
Mei Kong, Ph.D.Beckman Research Institute of the City of HopeDuarte, CATargeting Glutamine Metabolism and the B55a-p53 Survival Pathway for Lymphoma Treatment
Christopher A. Maher, Ph.D.Siteman Cancer CenterWashington UniversitySt. Louis, MOUnderstanding the Role of Polycomb Associated LncRNAs in Prostate Cancer2013 Vintner Grant – Funded by The Wine CelebrationIn Honor of Fred and Mary Constant, Jeff and Valerie Gargiulo, Dick and Ann Grace, Fred and Sally Schweiger, and Lowell and Janet Herrero
Michael Kharas, Ph.D.Memorial Sloan-Kettering Cancer CenterNew York, NYUnderstanding the MSI2 RNA Binding Protein Network in Leukemia
George-Lucian Moldovan, Ph.D.Penn State Hershey Cancer InstituteHershey, PA Dysregulation of the PARI Genomic Stability Pathway in Leukemia
Zeshaan Rasheed, M.D., Ph.D.The Sidney Kimmel Comprehensive Cancer CenterBaltimore, MDRegulatory Effects of the Tumor Microenvironment on Stem Cell Plasticity in Pancreatic Ductal Adenocarcinoma
Jatin Roper, M.D.Tufts Medical CenterBoston, MAThe Role of IWS1 and FGFR2 Isoform IIIc in Akt Isoform-dependent Colorectal Carcinogenesis
Ryan A. Wilcox, M.D., Ph.D.University of Michigan Comprehensive Cancer CenterAnn Arbor, MIRole of the T-cell Transcription Factor GATA-3 in Cutaneous T-cell Lymphomas
Kris C. Wood, Ph.D.Duke Cancer InstituteDurham, NCSystematic Identification of Combination Therapies Targeting the Breast Cancer Microenvironment2013 V Foundation Wine Celebration Vounteer Grant in Honor of John and Anne Sachs
Chunling Yi, Ph.D.Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashington, DCInterrogating the Role of Hippo-Yap Growth Regulatory Pathway in Kidney Cancer
2013 Annual Report5
2 0 1 3 T r a n S l aT i o n a l G r a n T S
Nika Danial, Ph.D.Margaret Shipp, M.D.Jarrod Marto, Ph.D.Dana-Farber Cancer InstituteBoston, MAFueling DLBCL Proliferation and Survival: A Role for Fatty Acid Metabolism
Ralph Deberardinis, M.D., Ph.D.Kemp Kernstein, M.D., Ph.D.Children’s Medical Center Research Institute at Universtiy of Texas SouthwesternDallas, TXFunded in Memory of Christopher T. CarrollTranslational Studies in Lung Cancer Metabolism: Creating New Paradigms in Diagnosis and Therapy
Gianpietro Dotti, M.D.Cliona Rooney, Ph.D.Caridad Martinez, M.D.Dan L. Duncan Cancer Center at Baylor College of MedicineHouston, TXPrevention and Treatment of Viral Infections and Leukemic Relapse after Allogeneic Stem Cell Transplantation
Benjamin L. Ebert, M.D., Ph.D.Ann Mullally, M.D.William Kaelin, Jr., M.D.David Steensma, M.D.Brigham and Women’s HospitalBoston, MAIdentifying and Targeting Oncogenic Pathways in TET2 and IDH Mutant Myeloid Malignancies
Tanja A. Gruber, M.D., Ph.D.James R. Downing, M.D.St. Jude Children’s Research HospitalMemphis, TNFunded by the 2013 Dick Vitale Gala In Honor of Dick and Lorraine VitaleIdentification of Active Compounds in Infantile Acute Lymphoblastic Leukemia
John V. Heymach, M.D., Ph.D.Varsha Gandhi, Ph.D.Christine Stellrecht, Ph.D.Carlo Toniatti, M.D., Ph.D.Timothy Heffernan, Ph.D.The University of Texas MD Anderson Cancer CenterHouston, TXAttacking the Specific Vulnerability of LKB1-Mutant NSCLC to Energy Depletion Using an ATP Mimetic
Ite A.Laird-Offringa, Ph.D.Barbara Gitlitz, M.D.Martin W. Kast, Ph.D.Kimberly Siegmund, Ph.D.Lina Wang, M.D.Michael Wong, M.D., Ph.D.USC Norris Comprehensive Cancer CenterLos Angeles, CADevelopment of Immunotherapy for Small Cell Lung Cancer using Novel Modified Antigens
Daniela Matei, M.D.Kenneth P. Nephew, Ph.D.Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, INAn Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer
Toshi Tanuiguchi, M.D., Ph.D.Elizabeth M. Swisher, M.D.Fred Hutchinson Cancer CenterSeattle, WADefining Genomic Scarring and Functional DNA Variants that Predict Response to PARP Inhibitors in a Clinical Trial for Recurrent Ovarian Cancer
Pengbo Zhou, Ph.D.Leonard Salta, M.D.Yao-Tseng Chen, M.D., Ph.D.Weill Cornell Medical CollegeNew York, NYUbiquitin Ligase as a Novel Diagnostic Marker and Therapeutic Target for Colorectal CancerFunded by The V Foundation Wine CelebrationIn Honor of Steve Bornstein
2013 Grants
2013 Annual Report 6
2 0 1 3 D e S i G n aT e D G r a n T S
Lizi Wu, Ph.D.Shands Cancer CenterUniversity of FloridaGainesville, FLRegulation of Oncogenic NOTCH Signaling in Childhood LeukemiaFunded by 2012 Dick Vitale GalaIn Memory of Caleb Gacobbe
Daniel S. Wechsler, M.D., Ph.D.Duke University Medical CenterDurham, NCTherapeutic Targeting of Calm-AF10 Nuclear Export in Pediatric LeukemiaFunded by The Apple Gold Group
Stuart Goldberg, M.D.Hackensack University Medical CenterThe John Theurer Cancer CenterHackensack, NJThe Use of Dynamic Single Cell Network Profile to Predict Outcome in Newly Diagnosed Acute Myelogenous Leukemia (AML)Funded by Marketing Research ConsultantsIn Memory of Mary Ann Ingoglia
Victoria Belancio, Ph.D.Tulane UniversityTulane Cancer CenterNew Orleans, LALine-1 Contributing to Lung Cancer in VivoFunded by The Kay Yow Cancer Fund
Shari Pilon-Thomas, Ph.D.William E. Janssen, M.D.H. Lee Moffitt Cancer Center & Research InstituteTampa, FLAdoptive Cell Therapy for NeuroblastomaFunded by 2012 Dick Vitale GalaIn memory of Dave Heard
Queen of the Valley Medical CenterNapa, CAFunded by The V Foundation Wine CelebrationClinical Laboratory and Pathology ServicesHerman Family Advanced Diagnostic and Surgical Services Pavilion
Amit K. Verma, M.D.David J. Prezant, M.D.Mayris Webber, M.P.H., Dr. P.H.Charles B. Hall, Ph.D.Albert Einstein College of Medicine of Yeshiva Universi-tyBronx, NYEarly Detection of Hematologic Malignancies in New York City Firefighters Exposed to World Trade Center Dust after the 9/11 AttacksFunded by The V Foundation Wine Celebration and Jimmy V Celebrity Golf Classic
St. Helena HospitalNapa, CAClinical Research Program at St. Helena Hospital Martin-O’Neil Cancer CenterFunded by The V Foundation Wine Celebration
Calvin Lee, M.D.All Children’s HospitalSt. Petersburg, FLBMI1’s Role in the Regulation of Myogenic Differentiation in RhabdomyosarcomaFunded by 2013 Dick Vitale Gala
John Cavanagh, Ph.D.North Carolina State Jimmy V Cancer Therapeutics ProgramRaleigh, NC Funded by 2013 Jimmy V Celebrity Golf ClassicIn Honor of the JVCGC 20 Year Volunteers
James M. Ford, M.D.Stanford University School of MedicineStanford, CA Funded by The Gastric Cancer FoundationGastric Cancer Genomic Research
Daniel S. Wechsler, M.D., Ph.D.Catherine P. Lavau, DVM, Ph.D.Duke University Medical CenterDurham, NCA Novel Role for the CRM1 Nuclear Export Receptor in Leukemogenesis: Mechanisms and TargetingFunded by The Apple Gold Group
2013 Annual Report7
Jim AllegroEmeritus DirectorThe V Foundation for Cancer Research
Julie AllegroGeneral PartnerAllegro Venture Partners
Robert C. Bast, Jr., M.D.Vice President for Translational ResearchThe University of Texas MD Anderson Cancer Center
George BodenheimerExecutive ChairmanESPN, Inc.
Steven M. BornsteinFormer President and Chief Executive Officer NFL NetworkBoard ChairThe V Foundation for Cancer Research
Bill Cosby
George W. Dennis IIIRetired Senior PartnerTeague Campbell Dennis & Gorham, LLP
David B. FayRetired Executive DirectorUnited States Golf Association
Rosa M. GattiRetired Senior Vice President, Communications Counsel and Corporate OutreachESPN, Inc.
Mark KingPresidentAdidas Group North America
Philip H. KnightChairman of the BoardNike, Inc.
Michael W. KrzyzewskiHead Coach, Men’s BasketballDuke University
Eric LautenbachDirector of College Basketball Sports MarketingNike, Inc.
Carl C. Liebert IIIPresident USAA Capital Corporation
Robert E. LloydChair EmeritusThe V Foundation for Cancer Research
Joe LoughreyRetired President and Vice ChairmanCummins, Inc.
Michael C. Mac DonaldChairman and Chief Executive OfficerMedifast
Board of Directors
The V Foundation Board of Directors is entrusted with and
accountable for the strategic leadership and governance of the
organization. Comprised of prominent business leaders, award-
winning athletes and coaches, distinguished physicians and
world-renowned entertainers, the Board provides governance and
insight into sustaining and continually improving the Foundation’s
efforts in the fight against cancer.
2013 Annual Report 8
Michael E. MarksFounding PartnerRiverwood Capital, LLC
Geoffrey S. Mason Senior Production SpecialistESPN, Inc.
Joseph O. Moore, M.D.Professor of MedicineDuke Cancer Institute
Robert C. NakasoneRetired Chief Executive OfficerToys “R” Us, Inc.
Donna OrenderChief Executive OfficerOrender Unlimited, LLC
Lawrence F. Probst IIIChairman of the BoardElectronic Arts
Harry E. Rhoads, Jr.Chief Executive OfficerWashington Speakers Bureau
Robin RobertsCo-AnchorABC’s Good Morning America
John P. SaundersSports CommentatorESPN, Inc. and ABC Sports
Constance SkidmoreRetired Board Member – Managing Partner PricewaterhouseCoopers LLP
John SkipperCo-ChairDisney Media NetworksPresidentESPN, Inc.
Tony F. Smith, Ph.D.Managing DirectorLeadership Research Institute
Pamela Valvano StrasserChairwomanThe V Foundation for Cancer Research
Stuart TaylorChief Executive Officer The Taylor Group
Nicholas P. ValvanoPresident Emeritus The V Foundation for Cancer Research
Robert ValvanoSports Commentator
Lesley VisserSports CommentatorCBS and HBO
Dick VitaleSports CommentatorESPN, Inc. and ABC Sports
R.C. “Bucky” WatersRetired Vice ChancellorDuke University Medical Center
Robert P. WaymanRetired Chief Financial Officer and Executive Vice President Hewlett-Packard Company
Dereck WhittenburgDirector of Player DevelopmentNorth Carolina State University
David W. WilliamsRetired Senior Vice PresidentWhirlpool Corporation
Norby WilliamsonExecutive Vice President, Programming & AcquisitionsESPN, Inc.
Larry WoodardPresident and Chief Executive OfficerGraham Stanley Advertising
Susan BraunEx OfficioChief Executive Officer The V Foundation for Cancer Research
2013 Annual Report9
Scientific Advisory Committee
The Scientific Advisory Committee is composed of leading
physicians and research scientists from prominent universities
and cancer centers. The all-volunteer Committee reviews and
recommends top-rated research projects from the brightest
innovators exploring the mysteries of cancer. Their guidance
safeguards the scientific merit of grant proposals and ultimately
provides funding to the leading pioneers in the field of
cancer research.
Martin D. Abeloff, M.D. (In Memoriam) Sidney Kimmel Comprehensive Cancer Center
Robert C. Bast, Jr., M.D.The University of Texas MD Anderson Cancer Center
William T. Beck, Ph.D.University of Illinois at Chicago
Lisa Coussens, Ph. D. Oregon Health & Science University
Nancy Davidson, M.D. University of Pittsburgh Cancer Institute
H. Shelton Earp III, M.D.UNC Lineberger Comprehensive Cancer Center
Paul F. Engstrom, M.D.Fox Chase Cancer Center
Olivera J. Finn, Ph.D.University of Pittsburgh School of Medicine
Richard I. Fisher, M.D.Fox Chase Cancer Center
James M. Ford, M.D.Stanford University School of Medicine
2013 Annual Report 10
Susan Hilsenbeck, Ph.D.Baylor College of Medicine
Theodore S. Lawrence, M.D., Ph.D.University of Michigan Comprehensive Cancer Center
A. Thomas Look, M.D. Dana-Farber Cancer Institute
John D. Minna, M.D. University of Texas Southwestern Medical Center
Joseph O. Moore, M.D.Duke Cancer Institute
William G. Nelson, M.D., Ph.D.Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brian Patrick O’Neill, M.D. Mayo Clinic Cancer Center
Richard O’Reilly, M.D.Memorial Sloan-Kettering Cancer Center
David Piwinica-Worms, M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Helen Piwinica-Worms, Ph.D. The University of Texas MD Anderson Cancer Center
Jerome Ritz, M.D.Dana-Farber Cancer Institute
David E. Schuller, M.D.The Ohio State University Comprehensive Cancer Center
Jonathan W. Simons, M.D.Prostate Cancer Foundation
Margaret A. Tempero, M.D.UCSF Comprehensive Cancer Center
2013 Annual Report11
c U r r e n T a S S e T S :
Cash and cash equivalentsAccounts receivable, netPromises to give, net Prepaid expenses
T o Ta l c U r r e n T a S S e T S
Property and Equipment, Net
o T h e r a S S e T S :Investments Promises to give, netIntangible assets
T o Ta l o T h e r a S S e T S
T o Ta l a S S e T S
Statement of Financial Position
September 30, 2013
Assets
2 0 1 3
$ 11,730,389213,495
2,136,430151,737
14,232,051
48,515
22,446,4543,413,097
50,000
25,909,551
$40,190,117
2013 Annual Report 12
c U r r e n T l i a B i l i T i e S :
Accounts payable and accrued expenses Accrued payroll and related liabilitiesDeferred rent Grants payable
T o Ta l c U r r e n T l i a B i l i T i e S
lo n G -T e r ml i a B i l i T i e S :Grants payable, net
T o Ta l l i a B i l i T i e S
n e T a S S e T S :Unrestricted: Board designatedUndesignated
Temporarily restrictedPermanently restricted
T o Ta l n e Ta S S e T S
T o Ta l l i a B i l i T i e Sa n D n e T a S S e T S
2 0 1 3
$ 55,18853,96840,350
12,223,413
12,372,919
9,840,300
22,213,219
5,517,136(3,589,825)
1,927,3113,932,57612,117,011
17,976,898
$40,190,117
Liabilities & Net Assets
2013 Annual Report13
S U P P o r T a n D r e v e n U e :
Contributions and giftsSpecial events:Contributions Event incomeLess: costs of direct benefits to donorsNet revenues from special events
License incomeInvestment income, net of feesUnrealized gain on investmentsRealized gain on investments
Net assets released from restrictions
T o Ta l S U P P o r T a n D r e v e n U e
e X P e n S e S :Program ServicesSupporting Services:Management and generalFundraising expensesTotal Supporting Services
T o Ta l e X P e n S e S
c h a n G e S i n n e T a S S e T S
T r a n S f e r o f n e T a S S e T S
n e T a S S e T S – B e G i n n i n G o f n e w y e a r
n e T a S S e T S – e n D o f y e a r
U n r e S T r i c T e D $ 10,608,057
1,592,397204,611
(674,660)1,122,348
3,332117,605213,597130,773
12,195,7126,082,391
18,278,103
15,138,098
719,4901,071,164
1,790,654
16,928,752
1,349,351
3,785,000
(3,207,040)
$1,927,311
For the year ended September 30, 2013
Statement of Activities and Changes in Net Assets
2013 Annual Report 14
T e m P o r a r i lyr e S T r i c T e D
$ 5,085,610
–––––
266,906513,399314,326
6,180,241(6,082,391)
97,850
–
–––
–
P e r m a n e n T lyr e S T r i c T e D
$ 145,899
––––––––
145,889–
145,889
–
–––
–
2 0 1 3T o Ta l S
$ 15,839,566
1,592,397204,611
(674,660)1,122,348
3,332384,511
726,996445,099
18,521,852–
18,521,852
15,138,098
719,4901,071,164
1,790,654
16,928,752
1,593,100
–
16,383,798
$17,976,898
97,850
–
3,834,726
$3,932,576
145,899
(3,785,000)
15,756,112
$12,117,011
2013 Annual Report15
CA
MN
IL INOH
PA NJ
MD
MA
VA
NCTN
TX
FL
NY
AL
AZ
CO
CT
DC
GA
HI
IA
ID
KY
LA
ME
MI
MO
NE
NM
OR
SC
UT
WA
WI
WV
1994-2013
Grant Distribution by State
NHVT
2013 Annual Report 16
Grant Distributions by Cancer Site
Leukemia/Lymphoma ($22.1)
General Cancer/Other ($23.5)
Pediatric ($14.1)
Breast ($10.9)
GI ($4.0)
Lung ($11.6)
Melanoma ($6.3)
Prostate ($4.6)
Pancreatic ($5.5)
Gyn./Cervical/Ovarian ($3.1)
Brain ($3.3)
Head and Neck ($1.4)
Renal ($2.9)
Colon ($1.2)
Myeloma ($0.5)
Ewings ($0.8)
$115,436,0545 3 9 T o Ta l G r a n T S
1 9 9 4 - 2 0 1 3 ( i n m i l l i o n S )
2013 Annual Report17
Thank You
Thank You for Your Passion, Friendship and Commitment!
People from all walks of life support The V Foundation for Cancer Research.
Your donations are making an impact, advancing life-saving research and providing hope to cancer patients and their loved ones.
Thank you for caring and for all the good things you do to support our cause.
Together, we will win the fight against cancer.
2013 Annual Report1 2013 Annual Report 18
h o P e
Begins in the dark.The road is long.The hills are steep.
Only your support drives us forward.